The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS)
Authors:
- Raed AlRuwailiRARaed AlRuwaili
- Hayder M. Al-KuraishyHAHayder M. Al-Kuraishy
- Mubarak AlruwailiMAMubarak Alruwaili
- Amira Karam KhalifaAmira Karam Khalifa
- Athanasios AlexiouAAAthanasios Alexiou
- Marios PapadakisMPMarios Papadakis
- Hebatallah M. SaadHSHebatallah M. Saad
- Gaber El-Saber BatihaGaber El-Saber Batiha
Open Access
- 3 July 2023
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 479 (5) , 1267-1278
Abstract
Acute ischemic stroke (AIS) is a focal neurological disorder that accounts for 85% of all stroke types, due to occlusion of cerebral arteries by thrombosis and emboli. AIS is also developed due to cerebral hemodynamic abnormality. AIS is associated with the development of neuroinflammation which increases the severity of AIS. Phosphodiesterase enzyme (PDEs) inhibitors have neuro-restorative and neuroprotective effects against the development of AIS through modulation of the cerebral cyclic adenosine monophosphate (cAMP)/cyclic guanosine monophosphate (cGMP)/nitric oxide (NO) pathway. PDE5 inhibitors through mitigation of neuroinflammation may decrease the risk of long-term AIS-induced complications. PDE5 inhibitors may affect the hemodynamic properties and coagulation pathway which are associated with thrombotic complications in AIS. PDE5 inhibitors reduce activation of the pro-coagulant pathway and improve the microcirculatory level in patients with hemodynamic disturbances in AIS. PDE5 inhibitors mainly tadalafil and sildenafil improve clinical outcomes in AIS patients through the regulation of cerebral perfusion and cerebral blood flow (CBF). PDE5 inhibitors reduced thrombomodulin, P-selectin, and tissue plasminogen activator. Herein, PDE5 inhibitors may reduce activation of the pro-coagulant pathway and improve the microcirculatory level in patients with hemodynamic disturbances in AIS. In conclusion, PDE5 inhibitors may have potential roles in the management of AIS through modulation of CBF, cAMP/cGMP/NO pathway, neuroinflammation, and inflammatory signaling pathways. Preclinical and clinical studies are recommended in this regard. Graphical abstractKeywords
Funding Information
- Private Universität Witten/Herdecke gGmbH
This publication has 111 references indexed in Scilit:
- Nitric Oxide Donors as Neuroprotective Agents after an Ischemic Stroke-Related Inflammatory ReactionOxidative Medicine and Cellular Longevity, 2013
- Heart Disease and Stroke Statistics—2013 UpdateCirculation, 2013
- Inhaled Nitric Oxide Reduces Brain Damage by Collateral Recruitment in a Neonatal Stroke ModelStroke, 2012
- Recurrent ischemic stroke associated with sildenafil and tadalafil use in a young adultClinical Neurology and Neurosurgery, 2012
- Magnetic Resonance Imaging Investigation of Axonal Remodeling and Angiogenesis after Embolic Stroke in Sildenafil-Treated RatsJournal of Cerebral Blood Flow & Metabolism, 2008
- Additive Effects of Statin and Dipyridamole on Cerebral Blood Flow and Stroke ProtectionJournal of Cerebral Blood Flow & Metabolism, 2008
- Association of Ambulatory Blood Pressure With Ischemic Brain InjuryHypertension, 2007
- Adaptation of the hypothalamic blood flow to chronic nitric oxide deficiency is independent of vasodilator prostanoidsBrain Research, 2006
- Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregationBiochemical and Biophysical Research Communications, 2005
- Update on Clinical Trials of Tadalafil Demonstrates No Increased Risk of Cardiovascular Adverse EventsThe Journal of Sexual Medicine, 2004